GSK3B and Alzheimer disease: We found that Xn attenuated Aβ accumulation and tau phosphorylation via APP processing, GSK-3β and PP2A pathways as well as reducing ER and oxidative stress and related proteasome processing, properties consistent with therapeutic potential in AD and other progressive neurodegenerative disorders with AD-related neuropathology.